Common Contracts
2 similar Enters Into Agreement contracts by Alpine Immune Sciences, Inc.
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated...Enters Into Agreement • April 10th, 2024 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations
BOSTON and SEATTLE (BUSINESS WIRE) – April 10, 2024—Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated...Enters Into Agreement • April 10th, 2024 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations
BOSTON and SEATTLE (BUSINESS WIRE) – April 10, 2024—Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
